In reply

Rachel Pearlman; Albert De la Chapelle; Heather Hampel

doi:10.1001/jamaoncol.2017.1744

In reply

Rachel Pearlman
, Albert De la Chapelle
, Heather Hampel

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1587
Number of pages	1
Journal	JAMA Oncology
Volume	3
Issue number	11
DOIs	https://doi.org/10.1001/jamaoncol.2017.1744
State	Published - Nov 2017

Access to Document

10.1001/jamaoncol.2017.1744

Cite this

@article{f066940239fb454484fe935a53bf2c5a,

title = "In reply",

author = "Rachel Pearlman and \{De la Chapelle\}, Albert and Heather Hampel",

note = "Funding Information: Published Online: July 6, 2017. doi:10.1001/jamaoncol.2017.1744 Conflict of Interest Disclosures: Myriad Genetics Inc donated the next-generation sequencing testing for mismatch repair–proficient patients with CRC diagnosed younger than 50 years for this study. Dr de la Chapelle discloses a patent or intellectual property interest with Genzyme and Ipsogen. Ms Hampel discloses a consulting or advising role with Invitae Genetics and Genome Medical, research funding from Myriad Genetics, Inc (the donated testing for this study), and honoraria from Beacon LBS and Beijing Genomics Institute. No other disclosures are reported. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2017",

month = nov,

doi = "10.1001/jamaoncol.2017.1744",

language = "English",

volume = "3",

pages = "1587",

journal = "JAMA Oncology",

issn = "2374-2437",

number = "11",

}

TY - JOUR

T1 - In reply

AU - Pearlman, Rachel

AU - De la Chapelle, Albert

AU - Hampel, Heather

N1 - Funding Information: Published Online: July 6, 2017. doi:10.1001/jamaoncol.2017.1744 Conflict of Interest Disclosures: Myriad Genetics Inc donated the next-generation sequencing testing for mismatch repair–proficient patients with CRC diagnosed younger than 50 years for this study. Dr de la Chapelle discloses a patent or intellectual property interest with Genzyme and Ipsogen. Ms Hampel discloses a consulting or advising role with Invitae Genetics and Genome Medical, research funding from Myriad Genetics, Inc (the donated testing for this study), and honoraria from Beacon LBS and Beijing Genomics Institute. No other disclosures are reported. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2017/11

Y1 - 2017/11

UR - https://www.scopus.com/pages/publications/85042924967

U2 - 10.1001/jamaoncol.2017.1744

DO - 10.1001/jamaoncol.2017.1744

M3 - Letter

C2 - 28687820

AN - SCOPUS:85042924967

SN - 2374-2437

VL - 3

SP - 1587

JO - JAMA Oncology

JF - JAMA Oncology

IS - 11

ER -

In reply

Access to Document

Other files and links

Cite this